source
- Merck and Moderna report personalized mRNA vaccine delays melanoma recurrence in late-stage trialMerck and Moderna announced that a personalized mRNA cancer vaccine, when combined with standard therapy, slowed the return of melanoma and reduced its spread in a late-stage clinical study. The tr…
- Merck and Moderna report Phase 3 success for personalized mRNA cancer vaccine intismeran autogeneMerck and Moderna announced on August 19, 2026 that their personalized mRNA cancer vaccine, intismeran autogene, has completed a successful Phase 3 trial. The collaboration aims to create a patient…